United Therapeutics (UTHR) CFO exercises RSUs, shares withheld for taxes

Rhea-AI Filing Summary

United Therapeutics Corp CFO and Treasurer James Edgemond exercised restricted stock units into 19,478 shares of common stock on March 15, 2026. These awards converted one-for-one into common shares following vesting, reflecting performance-based and time-based equity compensation.

To cover tax obligations at vesting, 8,786 shares were withheld by United Therapeutics at a price of $536.12 per share. These F-code transactions are tax-withholding dispositions, not open-market sales. After all transactions, Edgemond directly holds 18,876 shares of common stock, including 42 shares acquired under the employee stock purchase plan.

Insights

Equity compensation analyst

Routine equity vesting with tax withholding; no open-market trading.

The CFO exercised restricted stock units into 19,478 common shares, a standard equity compensation event. The derivative code M signals option/RSU conversion rather than a market purchase, so this is primarily a shift from deferred to actual share ownership.

The company withheld 8,786 shares at $536.12 per share to satisfy tax liabilities, classified under F-code. These dispositions are not open-market sales and do not indicate a change in sentiment. Following the transactions, total direct holdings rise to 18,876 shares, suggesting a continued meaningful equity stake.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EDGEMOND JAMES

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO AND TREASURER

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		10,380	A	(1)	18,564(2)	D
Common Stock	03/15/2026		M		9,098	A	(1)	27,662	D
Common Stock	03/15/2026		F		4,682(3)	D	$536.12	22,980	D
Common Stock	03/15/2026		F		4,104(3)	D	$536.12	18,876	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/15/2026		M			10,380	(4)	(4)	Common Stock	10,380	$0.00	0.00	D
Restricted Stock Units	(1)	03/15/2026		M			9,098	(4)	(4)	Common Stock	9,098	$0.00	0.00	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

2. Includes 42 shares of common stock acquired on March 4, 2026 under the United Therapeutics Employee Stock Purchase Plan.

3. Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

4. Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2023.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did United Therapeutics (UTHR) CFO James Edgemond report in this Form 4?

He reported exercising restricted stock units into 19,478 shares of common stock on March 15, 2026. These awards vested and converted one-for-one into common shares as part of his equity compensation package with United Therapeutics Corporation.

Were any United Therapeutics (UTHR) shares sold by the CFO in the market?

No open-market sales are shown. The filing lists F-code transactions where 8,786 shares were withheld by United Therapeutics at $536.12 per share solely to cover tax obligations upon vesting of restricted stock units.

How many United Therapeutics (UTHR) shares does the CFO hold after these transactions?

After the reported Form 4 transactions, CFO James Edgemond directly holds 18,876 shares of United Therapeutics common stock. This amount includes 42 shares acquired under the United Therapeutics Employee Stock Purchase Plan on March 4, 2026.

What kind of equity awards did the United Therapeutics (UTHR) CFO exercise?

He exercised restricted stock units, each representing the right to receive one share of common stock after vesting. The filing notes that performance-based restricted stock units granted on March 15, 2023 vested and converted on a one-for-one basis into common shares.

Is the United Therapeutics (UTHR) CFO’s Form 4 transaction a strong bullish or bearish signal?

The activity appears routine rather than strongly bullish or bearish. It reflects vesting and exercise of restricted stock units with shares withheld for taxes, a common compensation event, while leaving the CFO with a continuing direct ownership position of 18,876 shares.